Read the latest news about the volunteer-centered clinical research organization of reference to pharmaceutical and biotechnology sponsors for managing central nervous system clinical trials and developing innovative treatments worldwide.
Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for KarXT (xanomeline-trospium) for the treatment of schizophrenia in adults. The application has been granted a Prescription Drug User Fee Act (PDUFA) date of September 26, 2024.
Pillar Clinical Research was instrumental in the conduction of the clinical trials that tested KarXT in that our sites in Bentonville, AR, Chicago, Il, and Richardson, TX were involved.
Today, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a healthcare provider in certain healthcare facilities.
Pillar Clinical Research was instrumental in the conduction of the clinical trials that tested Zurzavae.
Sign up to receive updates, promotions, and sneak peaks of Swab Test.